amiodarone has been researched along with Metabolic Syndrome in 2 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "to study the association between the presence of the metabolic syndrome or right-sided heart failure and the prevalence of amiodarone induced liver disease." | 7.75 | Amiodarone hepatotoxicity in the context of the metabolic syndrome and right-sided heart failure. ( Gradus-Pizlo, I; Juliar, B; Kwo, PY; Mattar, W, 2009) |
| "to study the association between the presence of the metabolic syndrome or right-sided heart failure and the prevalence of amiodarone induced liver disease." | 3.75 | Amiodarone hepatotoxicity in the context of the metabolic syndrome and right-sided heart failure. ( Gradus-Pizlo, I; Juliar, B; Kwo, PY; Mattar, W, 2009) |
| "Nonalcoholic steatohepatitis (NASH) is defined histopathologically by the presence of macrovesicular steatosis, cellular ballooning, and inflammation." | 2.48 | A myriad of pathways to NASH. ( Larrain, S; Rinella, ME, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mattar, W | 1 |
| Juliar, B | 1 |
| Gradus-Pizlo, I | 1 |
| Kwo, PY | 1 |
| Larrain, S | 1 |
| Rinella, ME | 1 |
1 review available for amiodarone and Metabolic Syndrome
| Article | Year |
|---|---|
A myriad of pathways to NASH.
Topics: Amiodarone; Anti-Retroviral Agents; Bacterial Infections; Cannabis; Diet; Fatty Liver; Genetic Disea | 2012 |
1 other study available for amiodarone and Metabolic Syndrome
| Article | Year |
|---|---|
Amiodarone hepatotoxicity in the context of the metabolic syndrome and right-sided heart failure.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Amiodarone; Anti-Arrhythmia Agents; Aspartate | 2009 |